The Movement Disorders Section of Hannover Medical School, headed by Professor Dirk Dressler, was, again, the most active non-commercial botulinum toxin research group at the 4th International Congress on Botulinum and other Neurotoxins (Toxins 2019) in Copenhagen, which was organised by the International Neurotoxin Association (INA). The group contributed altogether 10 posters and one platform presentation. For the first time, data originating from the recently started cooperation with Shanghai Tongji Hospital of Tongji University School of Medicine were presented. The presentations included the first English bibliography of the Chinese botulinumtoxin drug Hengli® as well as studies on comparative potency measurements of Hengli®, Xeomin® und Botox® and on bilateral Hengli® applications in hemifacial spasms. Three studies were dealing with the use of Xeomin® in spasticity and in ALS-induced hypersalivation, one study with antigenicity of daxibotulinumtoxin®, a new botulinum toxin drug development project, and one study each on the safety of botulinum toxin therapy in patients with anticoagulation, on quality of life in botulinum toxin therapy of cervical dystonia and on the history of botulinum toxin therapy in Germany. During his platform presentation Professor Dressler explored the safety of high-frequency botulinum toxin therapy which had recently lead to substantial improvement of botulinum toxin therapy results.
‘We were very pleased with the course of this congress. Our studies were well perceived. As co-founder of this congress and of INA I was pleased to see that the congress has now expanded to welcome more than 1500 participants.’ The biannual congress brings together basic scientists, users and manufacturers of botulinum toxin drugs from all over the world. It is the world-wide largest and most important congress on this topic.
Dirk Dressler, MD, PhD
Professor of Neurology
Prof. hon. (Univ. Santiago de Chile)
Movement Disorders Section
Hannover Medical School